Connect with us

Alzheimer's Research

Uncovering the Mystery: Research Suggests Single Unknown Respiratory Virus Causes Kawasaki Disease

New research strongly suggests that Kawasaki disease is caused by a single respiratory virus that is yet to be identified. Findings contradict the theory that many different pathogens or toxins could cause this disease that can lead to serious cardiac complications in young children.

Avatar photo

Published

on

The discovery of a single unknown respiratory virus as the cause of Kawasaki disease is a major breakthrough in medical research. For over 50 years, the exact origin of this condition has been a mystery. However, recent findings from the Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago strongly suggest that a single respiratory virus is responsible for Kawasaki disease.

“We have compelling data that provide a clear direction for the field to identify and sequence the virus that causes Kawasaki disease in susceptible children,” said Anne Rowley, MD, pediatric infectious diseases expert and scientist at Manne Research Institute at Lurie Children’s. “This will be critical to advancing the diagnosis, treatment, and prevention of Kawasaki disease.”

Kawasaki disease is a relatively uncommon condition affecting mostly children between 6 months and 5 years of age. Currently, there is no diagnostic test for Kawasaki disease. Clinical signs include fever, rash, swelling of the hands and feet, irritation and redness of the whites of the eyes, swollen lymph glands in the neck, and irritation and inflammation of the mouth, lips, and throat.

Children with Kawasaki disease have a 20 percent chance of developing heart disease, while infants are at higher risk with a 50 percent chance of cardiac complications. The standard treatment is intravenous immunoglobulin and aspirin, which substantially decreases the risk of heart disease in patients with Kawasaki disease. Steroids may be added for the highest-risk patients.

In their study, Dr. Rowley and colleagues prepared antibodies from blood cells of children with Kawasaki disease to see what these antibodies would target in tissue samples of patients who died from the disease. They found that the antibodies recognized inclusion bodies, which are by-products of a virus, in all 20 tissue samples representing cases from the U.S. and Japan over 50 years.

“We saw the same inclusion bodies targeted in every tissue sample spanning five decades and two continents, which shows that we are dealing with one predominant virus causing Kawasaki disease,” said Dr. Rowley. “It appears to be a respiratory virus since the inclusion bodies were in the medium-sized airways. Going forward, we need to focus on studies of pathology specimens to gain understanding of what is inside the inclusion bodies so that we can identify the Kawasaki disease virus and finally solve the mystery.”

This work was supported by the National Institutes of Health grant R01AI150719 to Dr. Rowley, the Max Goldenberg Foundation, the Center for Kawasaki Disease at Ann & Robert H. Lurie Children’s Hospital of Chicago, the Northwestern University NUSeq Core Facility, and the Northwestern University Flow Cytometry Core Facility supported by Cancer Center Support Grant (NCI CA060553).

Alzheimer's

The Key to Protein Quality: Unraveling the Role of P97/VCP Enzyme

In neurodegenerative diseases such as Alzheimer’s or Parkinson’s, proteins accumulate in the body’s cells, fold incorrectly and clump together to form larger aggregates. Normally, cells are able to remove these aggregates themselves. However, if a certain enzyme is blocked, this clean-up process no longer works. The new findings provide a better understanding of the molecular basis of these processes.

Avatar photo

Published

on

The intricate dance of protein quality control within cells has been revealed by researchers led by biochemist Alexander Buchberger at Julius-Maximilians-Universität Würzburg (JMU). A recent study published in Nature Communications sheds light on the crucial role played by the ubiquitin-selective unfoldase p97/VCP enzyme in eliminating malformed proteins and aggresomes.

In cells, proteins are constantly being produced, assembled, transported, and broken down. This delicate balance is vital to prevent serious illnesses, as even small changes can have devastating consequences. To maintain this balance, cells have developed complex systems to control protein quality. One such system involves the formation of aggresomes – a type of cage that collects and isolates proteins prone to clumping.

While the formation of aggresomes has been extensively studied, their protein content and degradation pathways remained poorly characterized. The recent study changes this by revealing that the breakdown of aggresomes requires multiple players, with p97/VCP enzyme emerging as the most critical.

The researchers conducted experiments blocking p97/VCP enzyme and observed that aggresomes no longer disintegrated and were destroyed. This indicates that p97/VCP plays a pivotal role in breaking down aggresomes into smaller components. The findings have significant biomedical implications, particularly for understanding neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s disease.

Mutations in the p97/VCP enzyme cause neuro-muscular degenerative diseases, including certain forms of dementia and ALS – amyotrophic lateral sclerosis. Moreover, disrupted degradation processes within cells could also contribute to Parkinson’s disease, which is characterized by Lewy bodies – roundish inclusions containing harmful protein deposits that disrupt nerve cell metabolism.

The research team concludes that their findings suggest mutations in the p97/VCP enzyme disrupt aggresome degradation, potentially contributing to Lewy body formation and neuro-muscular degenerative diseases. This study highlights the importance of understanding protein quality control mechanisms within cells and how disruptions in these processes can lead to devastating diseases.

Continue Reading

Alzheimer's

The Surprising Link Between Curiosity and Healthy Aging

Psychology literature has shown that curiosity tends to decline with age. Psychologists shows one type of curiosity can increase well into old age, contradicting prior research. Older adults who maintain curiosity and want to learn new things relevant to their interests may be able to offset or even prevent Alzheimer’s disease. Conversely, those who show muted curiosity and disinterest may be at risk for dementia.

Avatar photo

Published

on

The secret to aging successfully may not be what you think. Instead of focusing on physical exercise or mental stimulation alone, research suggests that cultivating curiosity can play a significant role in maintaining cognitive health and even preventing Alzheimer’s disease. An international team of psychologists has found that older adults who maintain a curious mindset and seek out new knowledge relevant to their interests may be able to offset or prevent dementia.

This finding challenges prior research that suggested curiosity decreases with age. The study, published in the journal PLOS One, was led by UCLA psychologist Alan Castel and involved a large sample of participants between the ages of 20 and 84. The researchers aimed to tease apart two types of curiosity: trait curiosity (a general level of inquisitiveness) and state curiosity (a momentary feeling of curiosity experienced when engaging with specific topics).

To assess these forms of curiosity, the researchers asked participants to complete an online questionnaire and guess answers to hard trivia questions. Analysis showed that while trait curiosity did decline across the adult lifespan, state curiosity increased sharply after middle age and continued upward well into old age.

The study’s lead author, Mary Whatley, notes that this finding may be related to selectivity theory, which suggests that as people get older, they become more selective about what they want to learn. This aligns with research on lifelong learning, where many older adults engage in activities like taking classes or picking up hobbies.

Castel’s own work on memory has shown that people tend to quickly forget information that doesn’t engage their curiosity. Anecdotally, many older adults report that staying curious is crucial for maintaining cognitive health and preventing dementia.

This study was supported by the National Institutes of Health’s National Institute on Aging, the Leverhulme Trust, and the Alexander von Humboldt Foundation. The findings suggest that cultivating curiosity can be a key factor in healthy aging and may even help prevent or offset Alzheimer’s disease.

Continue Reading

Alzheimer's

“Unlocking Brain Resilience: Researchers Discover CLU Protein’s Potential to Protect Against Alzheimer’s Disease”

Recently approved Alzheimer’s drugs offer a step forward for treating the disease, but new therapeutic strategies are needed to complement them and provide personalized therapeutic approaches. Researchers have identified a potential strategy to protect against Alzheimer’s disease by increasing the clusterin protein (CLU).

Avatar photo

Published

on

As scientists continue to search for effective treatments for Alzheimer’s disease, a recent study has shed light on a promising new approach. Researchers at Mass General Brigham have discovered that increasing levels of the “CLU” (clusterin) protein may protect against cognitive decline and potentially provide a complementary therapy to existing treatments.

Led by Dr. Tracy Young-Pearse, the research team used various models, including human brain tissue from over 700 participants and animal models, to uncover the molecular role of CLU in protecting against neurodegeneration. Their findings suggest that increasing CLU can prevent inflammatory interactions between brain cells called astrocytes and microglia, which are associated with heightened inflammation.

The study’s results have significant implications for the design and testing of new therapeutic strategies for Alzheimer’s disease. As Dr. Young-Pearse noted, “Increasing clusterin has the potential to prevent cognitive decline in a way that is different than and complementary to anti-amyloid therapies to promote brain resilience.”

CLU may also be beneficial for treating other age-related brain diseases, many of which share similar mechanisms of neuroinflammatory dysregulation. The researchers emphasize the importance of personalized therapeutic approaches, as individuals’ responses to CLU upregulation vary based on their genetics.

The study’s findings provide a crucial step forward in the search for effective treatments for Alzheimer’s disease and other age-related brain diseases. By understanding the role of CLU in protecting against neurodegeneration, researchers can develop new strategies to promote brain resilience and potentially prevent cognitive decline.

In conclusion, the discovery of CLU’s potential therapeutic benefits offers new hope for individuals affected by Alzheimer’s disease and other age-related brain disorders. Further research is necessary to fully explore this promising approach, but the findings of this study mark an important milestone in the pursuit of effective treatments for these debilitating diseases.

Continue Reading

Trending